

Transaction Contacts

<u>Coverage Team:</u> Dan Dubin, M.D. <u>Sean Pitt</u> ECM Team: Rahul Chaudhary Patrick Morley

aura

\$80 Million Follow-On Offering

SVD> Securities Lead-Left Bookrunner November 2022

SVB Securities Serves as Lead-Left Bookrunner for Aura Biosciences' (Nasdaq: AURA) \$80 Million Follow-On Offering

Key Transaction Highlights

- Confidentially launched on November 28th, publicly launched November 30th (post-close), and priced overnight
- · Well oversubscribed from both new and existing investors
- Consisted of 6,700,000 shares of common stock at a price of \$12.00 per share, representing a 13.0% discount to confidential launch
- Aura Biosciences intends to use the net proceeds from this offering together with existing cash, cash
 equivalents and marketable securities, to advance the clinical development of belzupacap sarotalocan for the
 treatment of choroidal melanoma and NMIBC, to develop the platform and for general corporate purposes.
- This is SVB Securities' 2nd bookrun offering for Aura Biosciences and 47th bookrun equity offering in 2022.

If you would like to unsubscribe from this distribution, click here. If you would like to unsubscribe from all SVB Securities distributions, click here.

THIS EMAIL IS FOR INFORMATIONAL PURPOSES ONLY AND IS BEING FURNISHED TO INVESTMENT BANKING CLIENTS OF SVB SECURITIES LLC. THE INFORMATION INCLUDED HEREIN IS FOR YOUR INFORMATION ONLY AND MAY NOT BE REPRODUCED FOR OR REDISTRIBUTED TO ANY OTHER PURPOSES. THESE SECURITIES HAVE BEEN SOLD. THIS EMAIL IS NOT AN OFFER TO SELL, AND IS NOT SOLICITING AN OFFER TO BUY, ANY SECURITIES.

BOSTON 53 State Street 40th Floor Boston, MA 02109 CHARLOTTE 227 West Trade Street Suite 2050 Charlotte, NC 28202 NASHVILLE 40 Burton Hills Boulevard Suite 200 Nashville, TN 37215 NEW YORK 1301 Avenue of the Americas 12th Floor New York, NY 10019 SAN FRANCISCO 255 California Street 12th Floor San Francisco, CA 94111

> An SVB Company svbsecurities.com